Oncology Models | Charles River Discovery Services

Neurotoxicity Model 

Peripheral neurotoxicity occurs in approximately 40 percent of previously untreated cancer patients who receive taxane-containing chemotherapy regimes. Because the effects of this therapy may limit treatment for a significant percentage of patients, the Charles River model that mimics clinical toxicity is significant. The model permits the evaluation of interactions of proposed protectant strategies for the disease and its treatment.

For more information about our neurotoxicity model, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 14 - New Models for Evaluating COPD or ...
May 11 - Expert Safety Testing to Accelerat...
Jun 17-Jun 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th European ...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 05-Jun 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Biol...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.